This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): TBC4746
Description: TBC4746 is a small molecule integrin antagonist that selectively binds to VLA-4 and prevents the firm attachment of the white blood cells to the vessel wall, thus precluding their migration to the inflammation site.
Deal Structure: In June 30, 2000, Texas Biotechnology Corporation (TBC) enteredinto a worldwide research collaboration and license agreement to discover,develop and commercialize VLA-4 antagonists with Schering-Plough. The primaryfocus of the collaboration will be to discover orally available VLA-4antagonists as treatments for asthma. Under the terms of the agreement,Schering-Plough obtains the exclusive worldwide rights to develop, manufactureand market all compounds from TBC's library of VLA-4 antagonists, as well as therights to a second integrin antagonist. TBC is responsible for optimizing a leadcompound and additional follow-on compounds. Schering-Plough is supportingresearch at TBC and will be responsible for all costs associated with theworldwide product development program and commercialization of the compound. Inaddition to reimbursing research costs, Schering-Plough paid an upfront licensefee and will pay development milestones and royalties on product sales resultingfrom the agreement....See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: